OncoMatch/Clinical Trials/NCT04734990
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Is NCT04734990 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Azacitidine and Seclidemstat for chronic myelomonocytic leukemia-0.
Treatment: Azacitidine · Seclidemstat — This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine may help block the formation of growths that may become cancer. Giving seclidemstat and azacytidine may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: ASXL1 mutation
Required: NRAS mutation
Required: RUNX1 mutation
Required: SETBP1 mutation
Required: TP53 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: hypomethylating agent (azacitidine, decitabine, guadecitabine, ASTX030, ASTX727)
No response after 6 cycles of azacitidine, decitabine, guadecitabine, ASTX030 or ASTX727 or relapse or progression after any number of cycles
Lab requirements
Kidney function
serum creatinine <= 1.5 x ULN OR creatinine clearance >= 50 ml/min for patients with creatinine > 1.5 x ULN
Liver function
total bilirubin < 2 x ULN (will allow < 5 x ULN if Gilbert's syndrome at investigator's discretion); AST or ALT <= 3 x ULN
Cardiac function
NYHA class III or IV congestive heart failure or LVEF < 50% by echocardiogram or MUGA scan excluded; history of MI within 6 months or unstable/uncontrolled angina or severe/uncontrolled ventricular arrhythmias excluded; QTcF >= 450 msecs and long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome excluded
Serum creatinine <= 1.5 x ULN OR creatinine clearance >= 50 ml/min... Adequate hepatic function with total bilirubin < 2 x ULN (will allow < 5 x ULN if Gilbert's syndrome at investigator's discretion)... AST or ALT <= 3 x ULN... NYHA class III or IV congestive heart failure or LVEF < 50% by echocardiogram or MUGA scan excluded; history of MI within 6 months or unstable/uncontrolled angina or severe/uncontrolled ventricular arrhythmias excluded; QTcF >= 450 msecs and long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify